Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Running, not enrolling · Not applicable

Conditions studied: Leukemia

In brief

This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will be tested for the KIR genes. If there is more than 1 donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable KIR genes. The study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. Transplant care will not change otherwise as a result of this study. This study is being done to demonstrate that AML patients who have donors with specific KIR and HLA genes will have a better outcome following transplant.

Key facts

Study ID

NCT02450708

Run by

Memorial Sloan Kettering Cancer Center

People needed

511

Starts

2015-05-01

Expected to finish

2027-05-01

Last updated by the study team

2026-06-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• RECIPIENT
• Persons of all ages are eligible for this study.
• Patient must have diagnosis of acute myelogenous leukemia (AML) at MSK or a collaborating treating institution. Patients with de novo AML or AML with preceding myelodysplastic syndrome (MDS) are eligible.
• Patient must be a potential candidate for an unrelated transplantation procedure at the time of enrollment even though patient may not be eligible for transplantation in the future due to relapse or presence of co-morbidity(ies).
• An unrelated donor does not need to be identified at the time of enrollment. If an HLA-compatible unrelated donor is not identified for the patient, the patient will be removed from the study.

You may not qualify if…

• Recipients with an available sibling donor matched at HLA-A, HLA-C, and HLA-DRB1 (excluding identical twin siblings).
• Patients for whom post-transplant treatment is planned are not excluded from enrollment.
• Patients with prior allogeneic hematopoietic cell transplantation for AML. Note: Patients who have undergone prior hematopoietic cell transplantation for a diagnosis other than AML are still eligible for this study.

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Hackensack University Medical Center Cancer Center — Hackensack, New Jersey, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Ohio State University — Columbus, Ohio, United States
• Baylor University Medical Center — Dallas, Texas, United States
• Md Anderson Cancer Center — Houston, Texas, United States
• University of Washington School of Medicine — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.